BMY (BMS) רווחיות מכירות לפי רווח גולמי

Leveraging a strong roster of scientists and R&D achievements to combat the patent cliff, Bristol-Myers Squibb (BMY) is expanding its oncology portfolio. The relative gross margin visualizes current production costs, where 66.30 determines the latest valuation metric. The business is currently investing in new molecules to maintain its market position and effectively counter the expansion of affordable generic manufacturers.
פילוחים אנליטיים ודוחות נתונים של חברת Bristol-Myers Squibb (BMY)

Gross margin determines the portion of revenue remaining after covering direct production costs. This ratio measures cost management efficiency, allowing for the real-time assessment of price fluctuations bypassing smoothed quarterly reports. By analyzing gross profit margins, an investor evaluates the stability of the operational foundation. For Bristol-Myers Squibb (BMY), this metric is critical when updating the portfolio through M&A and replacing expiring patents with new developments.